Medical University Of Graz

At the Medical University of Graz, researchers are evaluating new strategies to lower heart risk and improve vascular health. The focus includes testing innovative agents such as inclisiran to prevent major cardiovascular events, and assessing oral anticoagulants like Renaparin for better kidney graft outcomes after transplantation. Studies also target primary prevention of atherosclerosis and management of severe hypertriglyceridemia.

• Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Acute Coronary Syndrome risk reduction
• Severe Hypertriglyceridemia treatment
• Delayed graft function in kidney transplant recipients (vascular focus)

The department conducts 19 trials with about 70 investigators, positioning Graz as a hub for cardiovascular innovation in Europe.

The internal medicine team is advancing care for inflammatory bowel conditions by testing novel oral compounds and biologics. Trials examine the impact of obefazimod on ulcerative colitis remission and the safety of AGMB-129 in fibrostenotic Crohn’s disease. Additional work evaluates endoscopic improvement and symptom control.

• Moderate to severe ulcerative colitis
• Fibrostenotic Crohn’s disease
• Endoscopic improvement endpoints
• Novel oral therapies for inflammatory bowel disease

With a strong focus on gastrointestinal health, the Graz site leverages its academic environment to accelerate therapeutic options for patients across Austria.

Research at the university includes trials aimed at improving outcomes for women with reproductive cancers and hormonal disorders. A Phase 3 study evaluates navtemadlin as maintenance therapy for advanced or recurrent endometrial cancer, while other projects explore supportive care for pregnancy‑related complications.

• Advanced or recurrent endometrial cancer
• Maintenance therapy strategies
• Hormonal regulation in reproductive health
• Supportive interventions during pregnancy

The department’s multidisciplinary approach brings together oncologists, endocrinologists, and obstetric specialists to refine treatments for female health.

Investigators are probing immune‑modulating agents to treat chronic skin and systemic conditions. One study assesses the efficacy of povorcitinib in moderate to severe hidradenitis suppurativa, while another examines the role of ARGX‑117 in enhancing allograft tolerance by targeting complement pathways.

• Hidradenitis Suppurativa therapy
• Complement inhibition for transplant tolerance
• Immune checkpoint inhibition in cancer
• Autoimmune skin disease management

By integrating immunology expertise, the Graz site contributes to the development of targeted therapies that balance efficacy with safety.

The clinical program includes investigations of novel treatments for prostate and testicular conditions, though specific trials are in early stages. Current focus centers on evaluating biomarkers and therapeutic responses in male reproductive health.

• Biomarker discovery for prostate disease
• Therapeutic assessment in testicular disorders
• Hormonal modulation studies
• Early‑phase safety trials in male urogenital health

Although fewer trials are listed, the department maintains a collaborative network to expand research in male urogenital medicine.

Oncologic research at Graz tackles several solid tumors, testing cutting‑edge targeted agents and immunotherapies. Studies compare sotorasib versus pembrolizumab in KRAS‑mutated non‑small cell lung cancer and evaluate the combination of nivolumab with ipilimumab for colorectal cancer. Additional trials assess progression‑free survival in advanced cancers with novel compounds.

• KRAS p.G12C positive NSCLC
• PD‑L1 negative colorectal cancer
• Advanced stage IIIB/C nonsquamous NSCLC
• Combination checkpoint inhibitor therapy

With 19 active studies, the site’s oncology portfolio reflects a commitment to personalized medicine and global trial participation.

Metabolic health is addressed through trials targeting obesity, overweight, and related lipid disorders. Researchers test the effect of pegozafermin on fasting triglyceride levels in severe hypertriglyceridemia, and evaluate a multi‑dose regimen of AZD9550 in participants with obesity and type 2 diabetes. The goal is to improve metabolic parameters and reduce cardiovascular risk.

• Severe hypertriglyceridemia management
• Obesity and overweight treatment
• Type 2 diabetes metabolic control
• Lipid‑lowering peptide therapies

The interdisciplinary team at Medical University of Graz combines endocrinology and cardiology expertise to advance therapies for metabolic disorders.